0.2852

0.97% -0.0028

After Hours: .29 0.0048 +1.68%

IGC Pharma Inc (IGC)

Overview News Price History Option Chain Discussions Forecast Stock Split

IGC Pharma Inc stock is traded at $0.2852, with a volume of 317.52K. It is down -0.97% in the last 24 hours and down -15.42% over the past month. India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.

Previous Close:

$0.288

Open:

$0.278

24h Volume:

317.52K

Relative Volume:

0.29

Market Cap:

$28.55M

Revenue:

$1.20M

Net Income/Loss:

$-5.34M

P/E Ratio:

-4.6149

EPS:

-0.0618

Net Cash Flow:

$-6.27M

1W Performance:

+1.13%

1M Performance:

-15.42%

6M Performance:

-10.71%

1Y Performance:

-15.35%

1-Day Range:

$0.278

$0.2912

1-Week Range:

$0.2742

$0.3033

52-Week Range:

$0.242

$0.4985

IGC Pharma Inc Stock (IGC) Company Profile

Name

IGC Pharma Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

301-983-0998

Address

4336 Montgomery Avenue, Bethesda, MD

Employee

Twitter

@IGCIR

Next Earnings Date

2026-06-26

Latest SEC Filings

IGC's Discussions on Twitter

Compare IGC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IGC IGC Pharma Inc	0.2852	28.83M	1.20M	-5.34M	-6.27M	-0.0618
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

IGC Pharma Inc Stock (IGC) Latest News

May 23, 2026

IGC Pharma Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerTrading Community - Newser

May 23, 2026

May 22, 2026

IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill

May 22, 2026

May 21, 2026

IGC Pharma earnings beat, revenue topped estimates By Investing.com - Investing.com Australia

May 21, 2026

May 20, 2026

IGC Pharma (IGC) Q1 2026 Earnings: $-0.02 EPS Surges Past $-0.02 EstimatesEstimate Revision Count - Newser

May 20, 2026

IGC Pharma (IGC) Delivers Q1 2026 Beat — EPS $-0.02 vs $-0.02 ExpectedForward EPS Estimate - Newser

May 20, 2026

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - BioSpace

May 20, 2026

May 19, 2026

Drug trial for Alzheimer’s agitation reaches 80% enrollment at IGC Pharma - Stock Titan

May 19, 2026

May 18, 2026

IGC Pharma (IGC) Q1 2026 Earnings Surprise: EPS $-0.02, Up SignificantPopular Trader Picks - Newser

May 18, 2026

May 16, 2026

New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - Voice of Alexandria

May 16, 2026

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference - Black Hills Pioneer

May 16, 2026

May 15, 2026

IGC Pharma, Inc. Common Stock (NY: IGC - The Chronicle-Journal

May 15, 2026

IGC Pharma (NYSE: IGC) deepens Alzheimer’s R&D amid tight cash and new loans - Stock Titan

May 15, 2026

IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

IGC Unveils Tau-PET Biomarker Study for Alzheimer's at Global Ta - GuruFocus

May 15, 2026

IGC Pharma Presents Tau-PET Alzheimer’s Research - ACCESS Newswire

May 15, 2026

May 14, 2026

Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference - marketscreener.com

May 14, 2026

TradingKey - TradingKey

May 14, 2026

May 13, 2026

New Strong Buy Stocks for Oct. 24: IGC, ASM and More - MSN

May 13, 2026

May 09, 2026

New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN) - ChartMill

May 09, 2026

May 08, 2026

The key trends fueling IGC Pharma (IGC) growth potential (Institutional Selling) 2026-05-08Wall Street Picks - Newser

May 08, 2026

May 07, 2026

Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification - marketscreener.com

Apr 30, 2026

Apr 29, 2026

Cannabinoid Clinical Trials See Significant Growth for New… - Hemp Gazette

Apr 29, 2026

Cannabinoid Clinical Trials Gain Momentum: 50+ Companies Le… - Hemp Gazette

Apr 29, 2026

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase - BioSpace

Apr 29, 2026

Apr 28, 2026

As Alzheimer’s trial nears completion, IGC turns to caregivers - Stock Titan

Apr 28, 2026

Apr 25, 2026

New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - Scott Coop

Apr 25, 2026

Analysts Are Bullish on Top Healthcare Stocks: IGC Pharma (IGC), 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail

Apr 25, 2026

Apr 24, 2026

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion - itemonline.com

Apr 24, 2026

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia - Times Argus

Apr 24, 2026

Apr 23, 2026